Skip to content
naulon

No noticeNo retraction, correction or concern found when last checked on Nov 14, 2026.

The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries

Martin Hoenigl, Danila Seidel, Agostinho Carvalho and 14 more

The Lancet Microbe · 2022 · Review · CC BY

doi:10.1016/s2666-5247(21)00237-8 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Reports of COVID-19-associated mucormycosis have been increasing in frequency since early 2021, particularly among patients with uncontrolled diabetes. Patients with diabetes and hyperglycaemia often have an inflammatory state that could be potentiated by the activation of antiviral immunity to SARS-CoV2, which might favour secondary infections. In this Review, we analysed 80 published and unpublished cases of COVID-19-associated mucormycosis. Uncontrolled diabetes, as well as systemic corticosteroid treatment, were present in most patients with COVID-19-associated mucormycosis, and rhino-orbital cerebral mucormycosis was the most frequent disease. Mortality was high at 49%, which was particularly due to patients with pulmonary or disseminated mucormycosis or cerebral involvement. Furthermore, a substantial proportion of patients who survived had life-changing morbidities (eg, loss of vision in 46% of survivors). Our Review indicates that COVID-19-associated mucormycosis is associated with high morbidity and mortality. Diagnosis of pulmonary mucormycosis is particularly challenging, and might be frequently missed in India.

Abstract licence: CC BY-NC

References75

  1. 1.
  2. 2.

    Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020;21:e149-e162.

    Not in our library10.1016/s1473-3099(20)30847-1 (opens in a new tab)

  3. 3.

    Prattes J, Wauters J, Giacobbe DR, et al. Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Med. 2021;47:1158-1160.

    Not in our library10.1007/s00134-021-06471-6 (opens in a new tab)

  4. 4.
  5. 5.

    Poignon C, Blaize M, Vezinet C, Lampros A, Monsel A, Fekkar A. Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19. Clin Microbiol Infect. 2020;26:1582-1584.

    Not in our library10.1016/j.cmi.2020.06.026 (opens in a new tab)

  6. 6.

    Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021;21:e246-e257.

    Not in our library10.1016/s1473-3099(20)30784-2 (opens in a new tab)

  7. 7.

    Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405-e421.

    Not in our library10.1016/s1473-3099(19)30312-3 (opens in a new tab)

  8. 8.

    Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel). 2021;7:88.

    Not in our library10.3390/jof7020088 (opens in a new tab)

  9. 9.

    Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64:1028-1037.

    Not in our library10.1111/myc.13335 (opens in a new tab)

  10. 10.

    Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis. 2017;64:1619-1621.

    Not in our library10.1093/cid/cix130 (opens in a new tab)

  11. 11.

    Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52:706-712.

    Not in our library10.1016/j.ijantimicag.2018.08.005 (opens in a new tab)

  12. 12.

    Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323.

    Not in our library10.1001/jama.2020.2648 (opens in a new tab)

  13. 13.

    Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693-704.

    Not in our library10.1056/nejmoa2021436 (opens in a new tab)

  14. 14.

    Morales-Franco B, Nava-Villalba M, Medina-Guerrero EO, et al. Host-pathogen molecular factors contribute to the pathogenesis of Rhizopus spp in diabetes mellitus. Curr Trop Med Rep. 2021.

    Not in our library10.1007/s40475-020-00222-1 (opens in a new tab)

  15. 15.

    Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363-374.

    Not in our library10.1038/s41577-020-0311-8 (opens in a new tab)

  16. 16.

    Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52:1144-1155.

    Not in our library10.1093/cid/cir122 (opens in a new tab)

  17. 17.

    Alexander BD, Lamoth F, Heussel CP, et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the Consensus Definitions of Fungal Disease from the EORTC/MSGERC. Clin Infect Dis. 2021;72(suppl 2):S79-S88.

    Not in our library10.1093/cid/ciaa1855 (opens in a new tab)

  18. 18.
  19. 19.
  20. 20.

    Bassetti M, Azoulay E, Kullberg BJ, et al. EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the Intensive Care Unit Working Group. Clin Infect Dis. 2021;72(suppl 2):S121-S127.

    Not in our library10.1093/cid/ciaa1751 (opens in a new tab)

  21. 21.

    Alekseyev K, Didenko L, Chauhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021;12:85-89.

    Not in our library10.14740/jmc3637 (opens in a new tab)

  22. 22.

    Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021;11:1029-1030.

    Not in our library10.1002/alr.22785 (opens in a new tab)

  23. 23.

    Khan NGC, Martinez DV, Proud KC. A case report of COVID-19 associated pulmonary mucormycosis. Arch Clin Cases. 2020;7:46-51.

    Not in our library10.22551/2020.28.0703.10172 (opens in a new tab)

  24. 24.
  25. 25.

    Sargin F, Akbulut M, Karaduman S, Sungurtekin H. Severe rhinocerebral mucormycosis case developed after COVID-19. J Bacteriol Parasitol. 2021;12.

    Not in our library

  26. 26.

    Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol. 2021.

    Not in our library10.1177/11206721211009450 (opens in a new tab)

  27. 27.

    Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021;13.

    Not in our library10.7759/cureus.13163 (opens in a new tab)

  28. 28.
  29. 29.

    Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient—case report and review of literature. J Mycol Med. 2021;31.

    Not in our library10.1016/j.mycmed.2021.101125 (opens in a new tab)

  30. 30.

    Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J Fungi (Basel). 2021;7:174.

    Not in our library10.3390/jof7030174 (opens in a new tab)

  31. 31.

    Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now. 2021;51:633-635.

    Not in our library10.1016/j.idnow.2021.01.010 (opens in a new tab)

  32. 32.

    Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.

    Not in our library10.1016/j.ajem.2020.09.032 (opens in a new tab)

  33. 33.

    Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg. 2021;37:e40-e80.

    Not in our library10.1097/iop.0000000000001889 (opens in a new tab)

  34. 34.

    Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186:289-298.

    Not in our library10.1007/s11046-021-00528-2 (opens in a new tab)

  35. 35.

    Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2021;12.

    Not in our library10.1080/01676830.2021.1903044 (opens in a new tab)

  36. 36.
  37. 37.
  38. 38.
  39. 39.
  40. 40.

    Monte ESD, Santos MELD, Ribeiro IB, et al. Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020;53:746-749.

    Not in our library10.5946/ce.2020.180 (opens in a new tab)

All 75 references

Cited by papers we hold4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.